{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T04:24:40Z","timestamp":1768364680003,"version":"3.49.0"},"reference-count":106,"publisher":"Bentham Science Publishers Ltd.","issue":"12","funder":[{"name":"PPSUS","award":["17\/2551-0001"],"award-info":[{"award-number":["17\/2551-0001"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Irinotecan (IRI) is a widely used chemotherapeutic drug, mostly used for first-line treatment of colorectal and pancreatic cancer. IRI doses are usually established based on patient\u2019s body surface area, an approach associated with large inter-individual variability in drug exposure and high incidence of severe toxicity. Toxic and therapeutic effects of IRI are also due to its active metabolite SN-38, reported to be up to 100 times more cytotoxic than IRI. SN-38 is detoxified by the formation of SN-38 glucuronide, through UGT1A1. Genetic polymorphisms in the UGT1A1 gene are associated to higher exposures to SN-38 and severe toxicity. Pharmacokinetic models to describe IRI and SN-38 kinetic profiles are available, with few studies exploring pharmacokinetic and pharmacogenetic-based dose individualization. The aim of this manuscript is to review the available evidence supporting pharmacogenetic and pharmacokinetic dose individualization of IRI in order to reduce the occurrence of severe toxicity during cancer treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>The PubMed database was searched, considering papers published in the period from 1995-2017, using the keywords irinotecan, pharmacogenetics, metabolic genotyping, dose individualization, therapeutic drug monitoring, pharmacokinetics and pharmacodynamics, either alone or in combination, with original papers being selected based on the presence of relevant data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>The findings of this review confirm the importance of considering individual patient characteristics to select IRI doses. Currently, the most straightforward approach for IRI dose individualization is UGT1A1 genotyping. However, this strategy is sub-optimal due to several other genetic and environmental contributions to the variable pharmacokinetics of IRI and its active metabolite. The use of dried blood spot sampling could allow the clinical application of limited sampling and population pharmacokinetic models for IRI doses individualization.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867325666180622141101","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T12:05:46Z","timestamp":1529669146000},"page":"2085-2107","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity"],"prefix":"10.2174","volume":"26","author":[{"given":"Roberta Zilles","family":"Hahn","sequence":"first","affiliation":[{"name":"Graduate Program on Toxicology and Analytical Toxicology, Universidade Feevale, Novo Hamburgo- RS, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Venzon","family":"Antunes","sequence":"additional","affiliation":[{"name":"Graduate Program on Toxicology and Analytical Toxicology, Universidade Feevale, Novo Hamburgo- RS, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone Gasparin","family":"Verza","sequence":"additional","affiliation":[{"name":"Graduate Program on Toxicology and Analytical Toxicology, Universidade Feevale, Novo Hamburgo- RS, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magda Susana","family":"Perassolo","sequence":"additional","affiliation":[{"name":"Graduate Program on Toxicology and Analytical Toxicology, Universidade Feevale, Novo Hamburgo- RS, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edna Sayuri","family":"Suyenaga","sequence":"additional","affiliation":[{"name":"Graduate Program on Toxicology and Analytical Toxicology, Universidade Feevale, Novo Hamburgo- RS, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilberto","family":"Schwartsmann","sequence":"additional","affiliation":[{"name":"Oncology Service, Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre-RS, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Linden","sequence":"additional","affiliation":[{"name":"Graduate Program on Toxicology and Analytical Toxicology, Universidade Feevale, Novo Hamburgo- RS, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.nec.2012.01.005","volume":"23","author":"Carrillo J.A.","year":"2012","unstructured":"Carrillo JA, Munoz CA. Alternative chemotherapeutic agents: nitrosoureas, cisplatin, irinotecan.","journal-title":"Neurosurg Clin N Am"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.nucmedbio.2013.03.004","volume":"40","author":"Kawamura K.","year":"2013","unstructured":"Kawamura K, Hashimoto H, Ogawa M, Yui J, Wakizaka H, Yamasaki T, Hatori A, Xie L, Kumata K, Fujinaga M, Zhang MR. Synthesis, metabolite analysis, and in vivo evaluation of [(11)C]irinotecan as a novel positron emission tomography (PET) probe.","journal-title":"Nucl Med Biol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jchromb.2016.02.012","volume":"1015-1016","author":"Basu S.","year":"2016","unstructured":"Basu S, Zeng M, Yin T, Gao S, Hu M. Development and validation of an UPLC-MS\/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ctrv.2006.07.001","volume":"32","author":"Fuchs C.","year":"2006","unstructured":"Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer.","journal-title":"Cancer Treat Rev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ejca.2017.05.025","volume":"81","author":"Petrelli F.","year":"2017","unstructured":"Petrelli F, Inno A, Ghidini A, Rimassa L, Tomasello G, Labianca R, Barni S. Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review.","journal-title":"Eur J Cancer"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ejca.2011.12.005","volume":"48","author":"Sch\u00f8nnemann K.R.","year":"2012","unstructured":"Sch\u00f8nnemann KR, Yilmaz M, Bjerregaard JK, Nielsen KM, Pfeiffer P, Phase II. Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer.","journal-title":"Eur J Cancer"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ejogrb.2013.06.035","volume":"170","author":"Ueda Y.","year":"2013","unstructured":"Ueda Y, Miyatake T, Nagamatsu M, Yamasaki M, Nishio Y, Yoshino K, Fujita M, Tsutsui T, Enomoto T, Kimura T. A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.cll.2008.05.004","volume":"28","author":"Algeciras-Schimnich A.","year":"2008","unstructured":"Algeciras-Schimnich A, O\u2019Kane DJ, Snozek CLH. Pharmacogenomics of tamoxifen and irinotecan therapies.","journal-title":"Clin Lab Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/fcp.12117","volume":"29","author":"Etienne-Grimaldi M.C.","year":"2015","unstructured":"Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, Loriot MA, Narjoz C, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouqui\u00e9 R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejps.2017.07.022","volume":"109","author":"Zashikhina N.N.","year":"2017","unstructured":"Zashikhina NN, Volokitina MV, Korzhikov-Vlakh VA, Tarasenko II, Lavrentieva A, Scheper T, R\u00fchl E, Orlova RV, Tennikova TB, Korzhikova-Vlakh EG. Self-assembled polypeptide nanoparticles for intracellular irinotecan delivery.","journal-title":"Eur J Pharm Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ctrv.2004.05.002","volume":"30","author":"Alimonti A.","year":"2004","unstructured":"Alimonti A, Gelibter A, Pavese I, Satta F, Cognetti F, Ferretti G, Rasio D, Vecchione A, Di Palma M. New approaches to prevent intestinal toxicity of irinotecan-based regimens.","journal-title":"Cancer Treat Rev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ctrv.2008.05.002","volume":"34","author":"Kweekel D.","year":"2008","unstructured":"Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity.","journal-title":"Cancer Treat Rev"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2016.08.001","volume":"50","author":"Lam S.W.","year":"2016","unstructured":"Lam SW, Guchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity.","journal-title":"Cancer Treat Rev"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"Wang-Gillam A.","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.","journal-title":"Lancet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1158\/1078-0432.CCR-09-1526","volume":"16","author":"van der Bol J.M.","year":"2010","unstructured":"van der Bol JM, Mathijssen RHJ, Creemers GJM, Planting AST, Loos WJ, Wiemer EAC, Friberg LE, Verweij J, Sparreboom A, de Jong FAAA. CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.","journal-title":"Clin Cancer Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/cpt.720","volume":"102","author":"Adiwijaya B.S.","year":"2017","unstructured":"Adiwijaya BS, Kim J, Lang I, Cs\u00f5szi T, Cubillo A, Chen J-S, Wong M, Park JO, Kim JS, Rau KM, Melichar B, Gallego JB, Fitzgerald J, Belanger B, Molnar I, Ma WW. Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.","journal-title":"Clin Pharmacol Ther"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1093\/annonc\/mdf337","volume":"13","author":"Xu Y.","year":"2002","unstructured":"Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.","journal-title":"Ann Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.bmcl.2016.12.085","volume":"27","author":"Martino E.","year":"2017","unstructured":"Martino E, Della Volpe S, Terribile E, Benetti E, Sakaj M, Centamore A, Sala A, Collina S. The long story of camptothecin: From traditional medicine to drugs.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"6804","DOI":"10.1128\/MCB.16.12.6804","volume":"16","author":"Morham S.G.","year":"1996","unstructured":"Morham SG, Kluckman KD, Voulomanos N, Smithies O. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection.","journal-title":"Mol Cell Biol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"48178","DOI":"10.18632\/oncotarget.18380","volume":"8","author":"Fan Y.","year":"2017","unstructured":"Fan Y, Mansoor N, Ahmad T, Khan RA, Czejka M, Sharib S, Yang D-H, Ahmed M. Physiologically based pharmacokinetic modeling for predicting irinotecan exposure in human body.","journal-title":"Oncotarget"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1745-7254.2007.00477.x","volume":"28","author":"Lu A.J.","year":"2007","unstructured":"Lu AJ, Zhang ZS, Zheng MY, Zou HJ, Luo XM, Jiang HL. 3D-QSAR study of 20 (S)-camptothecin analogs.","journal-title":"Acta Pharmacol Sin"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"15387","DOI":"10.1073\/pnas.242259599","volume":"99","author":"Staker B.L.","year":"2002","unstructured":"Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/bph.13317","volume":"173","author":"Huisman S.A.","year":"2016","unstructured":"Huisman SA, de Bruijn P, Ghobadi Moghaddam-Helmantel IM, IJzermans JNM, Wiemer EAC, Mathijssen RHJ, de Bruin RWF. Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice.","journal-title":"Br J Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00280-017-3344-3","volume":"80","author":"Zhang X.","year":"2017","unstructured":"Zhang X, Yin JF, Zhang J, Kong SJ, Zhang HY, Chen XM. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/1534735404270335","volume":"3","author":"Conklin K.A.","year":"2004","unstructured":"Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness.","journal-title":"Integr Cancer Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1124\/mi.7.3.6","volume":"7","author":"Chen Y.","year":"2007","unstructured":"Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St Clair DK. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues.","journal-title":"Mol Interv"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1023\/A:1013157727506","volume":"12","author":"Rothenberg M.L.","year":"2001","unstructured":"Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, Sharma A, Elfring GL, Petit RG, Locker PK, Miller LL, von Hoff DD, Phase I. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.","journal-title":"Ann Oncol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3892\/or.18.6.1613","volume":"18","author":"Poujol S.","year":"2007","unstructured":"Poujol S, Pinguet F, Ychou M, Abderrahim AG, Duffour J, Bressolle FMM. A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.","journal-title":"Oncol Rep"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1067\/mcp.2002.129502","volume":"72","author":"Klein C.E.","year":"2002","unstructured":"Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC, Ratain MJ, Kastrissios H. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.","journal-title":"Clin Pharmacol Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/oxfordjournals.annonc.a059109","volume":"6","author":"Chabot G.G.","year":"1995","unstructured":"Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, H\u00e9rait P, Armand JP, Bugat R. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.","journal-title":"Ann Oncol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1200\/JCO.1996.14.10.2688","volume":"14","author":"Canal P.","year":"1996","unstructured":"Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer.","journal-title":"J Clin Oncol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.1996.14.11.2959","volume":"14","author":"Saltz L.B.","year":"1996","unstructured":"Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP, Phase I. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.","journal-title":"J Clin Oncol"},{"key":"ref=33","first-page":"2747","volume":"4","author":"Sparreboom A.","year":"1998","unstructured":"Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ, van Alphen RJ, Mathijssen RH, Stoter G, Verweij J. Irinotecan (CPT-11) metabolism and disposition in cancer patients.","journal-title":"Clin Cancer Res"},{"key":"ref=34","first-page":"2236","volume":"6","author":"Pitot H.C.","year":"2000","unstructured":"Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL, Phase I. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.","journal-title":"Clin Cancer Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1200\/JCO.2000.18.1.195","volume":"18","author":"de Jonge M.J.A.","year":"2000","unstructured":"de Jonge MJA, Verweij J, de Bruijn P, Brouwer E, Mathijssen RHJ, van Alphen RJ, de Boer-Dennert MM, Vernillet L, Jacques C, Sparreboom A. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.","journal-title":"J Clin Oncol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0090-9556(24)15060-X","volume":"28","author":"Slatter J.G.","year":"2000","unstructured":"Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV, Lord RS. III Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.","journal-title":"Drug Metab Dispos"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1373\/clinchem.2003.023481","volume":"49","author":"Poujol S.","year":"2003","unstructured":"Poujol S, Pinguet F, Malosse F, Astre C, Ychou M, Culine S, Bressolle F. Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies.","journal-title":"Clin Chem"},{"key":"ref=38","first-page":"3845","volume":"33","author":"Satoh T.","year":"2013","unstructured":"Satoh T, Yasui H, Muro K, Komatsu Y, Sameshima S, Yamaguchi K, Sugihara K. Pharmacokinetic assessment of irinotecan, SN-38, and SN-38-glucuronide: a substudy of the FIRIS study.","journal-title":"Anticancer Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/bmc.1345","volume":"24","author":"Ramesh M.","year":"2010","unstructured":"Ramesh M, Ahlawat P, Srinivas NR. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives.","journal-title":"Biomed Chromatogr"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1006\/abio.2001.5317","volume":"297","author":"Boyd G.","year":"2001","unstructured":"Boyd G, Smyth JF, Jodrell DI, Cummings J. High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells.","journal-title":"Anal Biochem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s00280-005-0166-5","volume":"58","author":"Poujol S.","year":"2006","unstructured":"Poujol S, Bressolle F, Duffour J, Abderrahim AG, Astre C, Ychou M, Pinguet F. Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10147-013-0558-1","volume":"19","author":"Hirose K.","year":"2014","unstructured":"Hirose K, Yamashita K, Takada H, Kaneda N, Fukami K, Maruo E, Kitamura M, Hasegawa J, Maeda Y. Usefulness of one-point plasma SN-38G\/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.","journal-title":"Int J Clin Oncol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/00007691-200404000-00027","volume":"26","author":"van Schaik R.H.N.","year":"2004","unstructured":"van Schaik RHN. Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents.","journal-title":"Ther Drug Monit"},{"key":"ref=44","first-page":"2012","volume":"6","author":"Santos A.","year":"2000","unstructured":"Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A, Vassal G. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.","journal-title":"Clin Cancer Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1200\/JCO.2002.08.177","volume":"20","author":"Kehrer D.F.S.","year":"2002","unstructured":"Kehrer DFS, Mathijssen RHJ, Verweij J, de Bruijn P, Sparreboom A. Modulation of irinotecan metabolism by ketoconazole.","journal-title":"J Clin Oncol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/jnci\/94.16.1247","volume":"94","author":"Mathijssen R.H.J.","year":"2002","unstructured":"Mathijssen RHJ, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John\u2019s wort on irinotecan metabolism.","journal-title":"J Natl Cancer Inst"},{"key":"ref=47","first-page":"4725","volume":"60","author":"Khanna R.","year":"2000","unstructured":"Khanna R, Morton CL, Danks MK, Potter PM. Proficient metabolism of irinotecan by a human intestinal carboxylesterase.","journal-title":"Cancer Res"},{"key":"ref=48","first-page":"1189","volume":"60","author":"Humerickhouse R.","year":"2000","unstructured":"Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.","journal-title":"Cancer Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bcp.2010.09.001","volume":"81","author":"Hatfield M.J.","year":"2011","unstructured":"Hatfield MJ, Tsurkan L, Garrett M, Shaver TM, Hyatt JL, Edwards CC, Hicks LD, Potter PM. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11.","journal-title":"Biochem Pharmacol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/1535-7163.MCT-13-0541","volume":"13","author":"Iusuf D.","year":"2014","unstructured":"Iusuf D, Ludwig M, Elbatsh A, van Esch A, van de Steeg E, Wagenaar E, van der Valk M, Lin F, van Tellingen O, Schinkel AH. OATP1A\/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice.","journal-title":"Mol Cancer Ther"},{"key":"ref=51","unstructured":""},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1200\/JCO.2008.20.6300","volume":"27","author":"Innocenti F.","year":"2009","unstructured":"Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ram\u00edrez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.","journal-title":"J Clin Oncol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00280-009-1138-y","volume":"66","author":"Sai K.","year":"2010","unstructured":"Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Matsumura Y, Ohtsu A, Saijo N, Minami H. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics\/pharmacodynamics in Japanese cancer patients.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1200\/JCO.2014.55.2307","volume":"32","author":"Innocenti F.","year":"2014","unstructured":"Innocenti F, Schilsky RL, Ram\u00edrez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.","journal-title":"J Clin Oncol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1158\/1078-0432.CCR-09-2936","volume":"16","author":"Ratain M.J.","year":"2010","unstructured":"Ratain MJ, Innocenti F. Individualizing dosing of irinotecan.","journal-title":"Clin Cancer Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2174\/138920011798062283","volume":"12","author":"Di Paolo A.","year":"2011","unstructured":"Di Paolo A, Bocci G, Polillo M, Del Re M, Di Desidero T, Lastella M, Danesi R. Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.","journal-title":"Curr Drug Metab"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3892\/ol.2011.533","volume":"3","author":"Hirose K.","year":"2012","unstructured":"Hirose K, Kozu C, Yamashita K, Maruo E, Kitamura M, Hasegawa J, Omoda K, Murakami T, Maeda Y. Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene.","journal-title":"Oncol Lett"},{"key":"ref=58","first-page":"3723","volume":"54","author":"Gupta E.","year":"1994","unstructured":"Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.","journal-title":"Cancer Res"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.1996.14.7.2012","volume":"14","author":"Mick R.","year":"1996","unstructured":"Mick R, Gupta E, Vokes EE, Ratain MJ. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.","journal-title":"J Clin Oncol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2165\/00003088-199733040-00001","volume":"33","author":"Chabot G.G.","year":"1997","unstructured":"Chabot GG. Clinical pharmacokinetics of irinotecan.","journal-title":"Clin Pharmacokinet"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1158\/1078-0432.CCR-1585-3","volume":"10","author":"Masi G.","year":"2004","unstructured":"Masi G, Falcone A, Di Paolo A, Allegrini G, Danesi R, Barbara C, Cupini S, Del Tacca M. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.","journal-title":"Clin Cancer Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/annonc\/mdt002","volume":"24","author":"Roy A.C.","year":"2013","unstructured":"Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.","journal-title":"Ann Oncol"},{"key":"ref=63","first-page":"6921","volume":"60","author":"Ando Y.","year":"2000","unstructured":"Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.","journal-title":"Cancer Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/sj.tpj.6500072","volume":"2","author":"Iyer L.","year":"2002","unstructured":"Iyer L, Das S, Janisch L, Wen M, Ram\u00edrez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.","journal-title":"Pharmacogenomics J"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","volume":"22","author":"Innocenti F.","year":"2004","unstructured":"Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ram\u00edrez J, Rudin CM, Vokes EE, Ratain MJ. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.","journal-title":"J Clin Oncol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/sj.bjc.6602042","volume":"91","author":"Marcuello E.","year":"2004","unstructured":"Marcuello E, Alt\u00e9s A, Menoyo A, Del Rio E, G\u00f3mez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.","journal-title":"Br J Cancer"},{"key":"ref=67","first-page":"259","volume":"4","author":"McLeod H.L.","year":"2006","unstructured":"McLeod HL. Individualizing cancer chemotherapy.","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref=68","first-page":"1653","volume":"7","author":"Li M.","year":"2014","unstructured":"Li M, Wang Z, Guo J, Liu J, Li C, Liu L, Shi H, Liu L, Li H, Xie C, Zhang X, Sun W, Fang S, Bi X. Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer.","journal-title":"OncoTargets Ther"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1002\/cncr.25735","volume":"117","author":"Shulman K.","year":"2011","unstructured":"Shulman K, Cohen I, Barnett-Griness O, Kuten A, Gruber SB, Lejbkowicz F, Rennert G. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.","journal-title":"Cancer"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.2147\/OTT.S95149","volume":"8","author":"Xiao X.G.","year":"2015","unstructured":"Xiao XG, Xia S, Zou M, Mei Q, Zhou L, Wang SJ, Chen Y. The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer.","journal-title":"OncoTargets Ther"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2005.05.5400","volume":"24","author":"Toffoli G.","year":"2006","unstructured":"Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D\u2019Andrea M, Pasetto LM, Pessa S, Errante D, De Pangher V, Giusto M, Medici M, Gaion F, Sandri P, Galligioni E, Bonura S, Boccalon M, Biason P, Frustaci S. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.","journal-title":"J Clin Oncol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/FPC.0b013e328014341f","volume":"17","author":"Minami H.","year":"2007","unstructured":"Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N. Irinotecan pharmacokinetics\/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.","journal-title":"Pharmacogenet Genomics"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/sj.bjc.6605776","volume":"103","author":"Martinez-Balibrea E.","year":"2010","unstructured":"Martinez-Balibrea E, Abad A, Mart\u00ednez-Card\u00fas A, Gin\u00e9s A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massut\u00ed B, Carrato A, Layos L, Manzano JL, Moreno V. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.","journal-title":"Br J Cancer"},{"key":"ref=74","unstructured":""},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1124\/jpet.112.202242","volume":"345","author":"L\u00e9vesque E.","year":"2013","unstructured":"L\u00e9vesque E, B\u00e9langer A-S, Harvey M, Couture F, Jonker D, Innocenti F, Cecchin E, Toffoli G, Guillemette C. Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil\/irinotecan-based regimens.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s00280-013-2161-6","volume":"71","author":"Kim K.P.","year":"2013","unstructured":"Kim KP, Kim HS, Sym SJ, Bae KS, Hong YS, Chang HM, Lee JL, Kang YK, Lee JS, Shin JG, Kim TWAA. UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/bjc.2015.5","volume":"112","author":"Teft W.A.","year":"2015","unstructured":"Teft WA, Welch S, Lenehan J, Parfitt J, Choi YH, Winquist E, Kim RB. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.","journal-title":"Br J Cancer"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.lungcan.2007.12.003","volume":"63","author":"Han J-Y.","year":"2009","unstructured":"Han J-Y, Lim H-S, Park YH, Lee SY, Lee JS. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.","journal-title":"Lung Cancer"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/tpj.2010.10","volume":"11","author":"Glimelius B.","year":"2011","unstructured":"Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H, Bystr\u00f6m P, S\u00f8rbye H, Wadelius M. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.","journal-title":"Pharmacogenomics J"},{"key":"ref=80","unstructured":"https:\/\/www.pharmacogenomics.pha.ulaval.ca\/ugt-allelesnomenclature\/"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/jnci\/djm115","volume":"99","author":"Hoskins J.M.","year":"2007","unstructured":"Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.","journal-title":"J Natl Cancer Inst"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2174\/157016007780077202","volume":"5","author":"Saito Y.","year":"2007","unstructured":"Saito Y, Maekawa K, Ozawa S, Sawada J. Genetic polymorphisms and haplotypes of major drug metabolizing enzymes in east asians and their comparison with other ethnic populations.","journal-title":"Curr Pharmacogn"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/tpj.2016.58","volume":"17","author":"Campbell J.M.","year":"2017","unstructured":"Campbell JM, Stephenson MD, Bateman E, Peters MDJ, Keefe DM, Bowen JM. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.","journal-title":"Pharmacogenomics J"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00280-017-3306-9","volume":"79","author":"Chen X.","year":"2017","unstructured":"Chen X, Liu L, Guo Z, Liang W, He J, Huang L, Deng Q, Tang H, Pan H, Guo M, Liu Y, He Q, He J. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/bjc.2013.479","volume":"109","author":"Kim S.Y.","year":"2013","unstructured":"Kim SY, S. Hong. Y.; K Shim, E.; Kong, S.Y.; Shin, A.; Baek, J.Y.; Jung, K.H. S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.","journal-title":"Br J Cancer"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/cncr.22760","volume":"110","author":"Han J.Y.","year":"2007","unstructured":"Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.","journal-title":"Cancer"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1365-2125.2010.03695.x","volume":"70","author":"Sai K.","year":"2010","unstructured":"Sai K, Saito Y, Tatewaki N, Hosokawa M, Kaniwa N, Nishimaki-Mogami T, Naito M, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Tamura T, Yamada Y, Ohe Y, Yoshida T, Minami H, Ohtsu A, Matsumura Y, Saijo N, Okuda H. Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.","journal-title":"Br J Clin Pharmacol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/FPC.0b013e328364b6cf","volume":"23","author":"De Mattia E.","year":"2013","unstructured":"De Mattia E, Toffoli G, Polesel J, D\u2019Andrea M, Corona G, Zagonel V, Buonadonna A, Dreussi E, Cecchin E. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.","journal-title":"Pharmacogenet Genomics"},{"key":"ref=89","unstructured":""},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","volume":"89","author":"Swen J.J.","year":"2011","unstructured":"Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GAPJM, van Schaik RHN, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VHM, Guchelaar HJ. Pharmacogenetics: from bench to byte--an update of guidelines.","journal-title":"Clin Pharmacol Ther"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1365-2125.2011.04141.x","volume":"73","author":"Etienne-Grimaldi M-C.","year":"2012","unstructured":"Etienne-Grimaldi M-C, Bennouna J, Formento J-L, Douillard J-Y, Francoual M, Hennebelle I, Chatelut E, Francois E, Faroux R, El Hannani C, Jacob J-H, Milano G. Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.","journal-title":"Br J Clin Pharmacol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"e0147681","DOI":"10.1371\/journal.pone.0147681","volume":"11","author":"Lee L.S.U.","year":"2016","unstructured":"Lee LSU, Seng KY, Wang LZ, Yong WP, Hee KH, Soh TI, Wong A, Cheong PF, Soong R, Sapari NS, Soo R, Fan L, Lee SC, Goh BC. Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI.","journal-title":"PLoS One"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40262-018-0644-7","volume":"57","author":"de Man F.M.","year":"2018","unstructured":"de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.","journal-title":"Clin Pharmacokinet"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1093\/jnci\/djh298","volume":"96","author":"Mathijssen R.H.","year":"2004","unstructured":"Mathijssen RH, de Jong FA, van Schaik RHN, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J, Sparreboom A. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.","journal-title":"J Natl Cancer Inst"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0091270006295060","volume":"47","author":"Ramchandani R.P.","year":"2007","unstructured":"Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ, Gobburu JVS. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.","journal-title":"J Clin Pharmacol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1200\/JCO.2009.23.6125","volume":"28","author":"Toffoli G.","year":"2010","unstructured":"Toffoli G, Cecchin E, Gasparini G, D\u2019Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, Innocenti F. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil\/leucovorin in patients with metastatic colorectal cancer.","journal-title":"J Clin Oncol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1111\/j.1349-7006.2011.02030.x","volume":"102","author":"Satoh T.","year":"2011","unstructured":"Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasaki Y, Koizumi W, Kakeji Y, Ishizuka N, Hyodo I, Sakata Y. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and\/or UGT1A1*6 polymorphisms.","journal-title":"Cancer Sci"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/1759-7714.12407","volume":"8","author":"Fukuda M.","year":"2017","unstructured":"Fukuda M, Shimada M, Kitazaki T, Nagashima S, Hashiguchi K, Ebi N, Takayama K, Nakanishi Y, Semba H, Harada T, Seto T, Okamoto I, Ichinose Y, Sugio K, Phase I. Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).","journal-title":"Thorac Cancer"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1158\/1078-0432.CCR-16-1012","volume":"23","author":"Toffoli G.","year":"2017","unstructured":"Toffoli G, Sharma MR, Marangon E, Posocco B, Gray E, Mai Q, Buonadonna A, Polite BN, Miolo G, Tabaro G, Innocenti F. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer.","journal-title":"Clin Cancer Res"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.trsl.2013.12.009","volume":"164","author":"Lu C.Y.","year":"2014","unstructured":"Lu CY, Huang CW, Hu HM, Tsai HL, Huang CM, Yu FJ, Huang MY, Chang SF, Huang ML, Wang JY. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil\/leucovorin with irinotecan in a first-line setting.","journal-title":"Transl Res"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/bjc.2011.206","volume":"105","author":"Marcuello E.","year":"2011","unstructured":"Marcuello E, P\u00e1ez D, Par\u00e9 L, Salazar J, Sebio A, del Rio E, Baiget M. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil\/leucovorin as first-line treatment in advanced colorectal cancer.","journal-title":"Br J Cancer"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/jjco\/hyq197","volume":"41","author":"Yamashita K.","year":"2011","unstructured":"Yamashita K, Nagashima F, Fujita K, Yamamoto W, Endo H, Miya T, Narabayashi M, Kawara K, Akiyama Y, Ando Y, Ando M, Sasaki Y. Phase I\/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.","journal-title":"Jpn J Clin Oncol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/cpt.615","volume":"102","author":"Roncato R.","year":"2017","unstructured":"Roncato R, Cecchin E, Montico M, De Mattia E, Giodini L, Buonadonna A, Solfrini V, Innocenti F, Toffoli G. Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.","journal-title":"Clin Pharmacol Ther"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/14737140.2016.1192471","volume":"16","author":"Passero F.C.","year":"2016","unstructured":"Passero FC, Grapsa D, Syrigos KN, Saif MW. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.clinbiochem.2016.05.004","volume":"49","author":"Antunes M.V.","year":"2016","unstructured":"Antunes MV, Char\u00e3o MF, Linden R. Dried blood spots analysis with mass spectrometry: Potentials and pitfalls in therapeutic drug monitoring.","journal-title":"Clin Biochem"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jpba.2017.11.079","volume":"150","author":"Hahn R.Z.","year":"2018","unstructured":"Hahn RZ, Arnhold PC, Andriguetti NB, Schneider A, Kl\u00fcck HM, Dos Reis SL, Bastiani MF, Kael I, da Silva ACC, Schwartsmann G, Antunes MV, Linden R. Determination of irinotecan and its metabolite SN-38 in dried blood spots using high-performance liquid-chromatography with fluorescence detection.","journal-title":"J Pharm Biomed Anal"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/163188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T07:55:41Z","timestamp":1751702141000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/163188\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":106,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,7,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867325666180622141101","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}